Sign in

    Maja Pataki

    Research Analyst at Kepler

    Maja Pataki is Head of the Medical Devices Sector and Deputy Head of Swiss Research at Kepler Cheuvreux, specializing in equity research on medical technology and healthcare companies. She covers prominent firms such as Alcon and bioMérieux, frequently issuing recommendations and target prices; her recent performance metrics show a 33% success rate and an average return of -13.4% on rated stocks over the past year. Pataki began her analyst career at UBS from 1998 to 2011 before joining Kepler Cheuvreux in January 2012, building extensive sector expertise. She holds a degree from the University of Basel and is recognized for her deep analytical insights within the European medtech investment community.

    Maja Pataki's questions to GNNDY leadership

    Maja Pataki's questions to GNNDY leadership • Q3 2023

    Question

    Asked about the expected growth drivers for the enterprise market once it recovers, how the DKK 600 million in cost synergies relate to the 20% EBITA margin target for Hearing, and the reason for the growth slowdown in the Emerging Hearing business.

    Answer

    Long-term enterprise growth drivers like hybrid work remain intact, though the recovery timeline is uncertain. The announced synergies will support and increase the likelihood of achieving the 20% core Hearing margin target. The Emerging business (JabraEnhance.com) is growing according to plan, up 37% year-to-date, and is on track to reach profitability goals by late 2025 or early 2026.

    Ask Fintool Equity Research AI